01 8Flixabi
02 2Inflectra
03 6Inflectra/Remsima
04 26Remicade
05 2Remicade
06 3Renflexis
Main Therapeutic Indication : Immunology
Currency : USD
2019 Revenue in Millions : 625
2018 Revenue in Millions : 642
Growth (%) : -3
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 98
2019 Revenue in Millions : 68
Growth (%) : 44
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 3,747
2019 Revenue in Millions : 4,380
Growth (%) : -14
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 659
2019 Revenue in Millions : 625
Growth (%) : 5
Main Therapeutic Indication : Immunology
Currency : USD
2021 Revenue in Millions : 99
2020 Revenue in Millions : 98
Growth (%) : 2
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 427
2019 Revenue in Millions : 509
Growth (%) : -16
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 330
2019 Revenue in Millions : 411
Growth (%) : -20
Main Therapeutic Indication : Immunology
Currency : USD
2021 Revenue in Millions : 299
2020 Revenue in Millions : 330
Growth (%) : -9
Main Therapeutic Indication : Immunology
Currency : USD
2021 Revenue in Millions : 657
2020 Revenue in Millions : 659
Growth (%) : 0
Main Therapeutic Indication : Immunology
Currency : USD
2021 Revenue in Millions : 186
2020 Revenue in Millions : 135
Growth (%) : 38
LOOKING FOR A SUPPLIER?
